However, this landscape shifted dramatically in late 2025: the Trump administration negotiated deals with Novo Nordisk and Eli Lilly to offer Wegovy and Zepbound at $245/month for Medicare and Medicaid, and CMS launched the BALANCE Model to begin Medicare Part D coverage of GLP-1s for obesity starting in 2027 (with a bridge demonstration in mid-2026) ( [5] )
Elucidating this issue is complicated by multiple confounding factors, including population heterogeneity, medication use, dietary and lifestyle variations, disease staging, and inconsistencies in research methodologies
Genome-Wide Association Study of Homocysteine in African Americans from the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Coronary Artery Risk in Young Adults Study. Journal of Human Genetics, vol
Best Alternative to Amazon One Medical GLP-1 Program Amazon's GLP-1 program is well-designed for a specific patient profile: insured patients in One Medical markets who want their weight loss treatment integrated into primary care and are comfortable with a more involved clinical onboarding process
Follow me for more drug pricing analysis (Bryce Platt, PharmD) Big move